{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:06:42Z","timestamp":1794938802742,"version":"4.9.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jaad.2023.12.048","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T02:51:39Z","timestamp":1707360699000},"page":"945-952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of crisaborole ointment, 2%, in participants aged \u226545\u00a0years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study"],"prefix":"10.1016","volume":"90","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Kirsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Annis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbo","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie L.","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2023.12.048_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0733-8635(03)00113-X","article-title":"Skin diseases of the lower extremities in the elderly","volume":"22","author":"Theodosat","year":"2004","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.jaad.2023.12.048_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMra055289","article-title":"Chronic venous disease","volume":"355","author":"Bergan","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2023.12.048_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40257-016-0250-0","article-title":"Stasis dermatitis: pathophysiology, evaluation, and management","volume":"18","author":"Sundaresan","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.12.048_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13670-018-0257-x","article-title":"Stasis dermatitis: differentiation from other common causes of lower leg inflammation and management strategies","volume":"7","author":"Rzepecki","year":"2018","journal-title":"Curr Geriatr Rep"},{"issue":"8","key":"10.1016\/j.jaad.2023.12.048_bib5","first-page":"989","article-title":"Diagnosis and treatment of venous ulcers","volume":"81","author":"Collins","year":"2010","journal-title":"Am Fam Physician"},{"issue":"3","key":"10.1016\/j.jaad.2023.12.048_bib6","first-page":"339","article-title":"A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis","volume":"4","author":"Weiss","year":"2005","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.12.048_bib7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2023.12.048_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.31128\/AJGP-07-20-5507","article-title":"Selection of an effective topical corticosteroid","volume":"50","author":"Aung","year":"2021","journal-title":"Aust J Gen Pract"},{"issue":"4","key":"10.1016\/j.jaad.2023.12.048_bib9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1024\/0301-1526.33.4.260","article-title":"Successful treatment of stasis dermatitis with topical tacrolimus","volume":"33","author":"Dissemond","year":"2004","journal-title":"Vasa"},{"issue":"1","key":"10.1016\/j.jaad.2023.12.048_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.12.048_bib11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.jaad.2023.12.048_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.cellsig.2015.12.001","article-title":"Adaptive phenotypic modulation of human arterial endothelial cells to fluid shear stress-encoded signals: modulation by phosphodiesterase 4D-VE-cadherin signalling","volume":"28","author":"Rampersad","year":"2016","journal-title":"Cell Signal"},{"issue":"5","key":"10.1016\/j.jaad.2023.12.048_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40257-019-00450-w","article-title":"Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups","volume":"20","author":"Callender","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.12.048_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12533","article-title":"Crisaborole: a new and effective nonsteroidal topical drug for atopic dermatitis","volume":"30","author":"Kailas","year":"2017","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2023.12.048_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","article-title":"Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1)","volume":"21","author":"Schlessinger","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.12.048_bib17","unstructured":"Boguniewicz M, Simpson EL, Paller AS, et al. Crisaborole ointment, 2%, resulted in clinically significant improvement in the quality of life of patients with mild to moderate atopic dermatitis and their families. Presented at: Maui Derm 2017; June 14-17, 2017; Colorado Springs, Colorado."},{"key":"10.1016\/j.jaad.2023.12.048_bib18","unstructured":"Simpson E, Yosipovitch G, Bushmakin AG, et\u00a0al. Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: a mediation analysis. Presented at: Fall Clin Dermatol Conference; October 12-15, 2017 2017; Las Vegas, NV."},{"key":"10.1016\/j.jaad.2023.12.048_bib19","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Simpson E, Tan H, et al. The effect of crisaborole ointment, 2%, on pruritus in patients with atopic dermatitis (AD): an extended analysis. Presented at: 2017 Fall Clin Dermatol Conference; October 12-15, 2017 2017; Las Vegas, NV.","DOI":"10.25251\/skin.1.supp.38"},{"issue":"8","key":"10.1016\/j.jaad.2023.12.048_bib20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2217\/imt-2016-0023","article-title":"Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies","volume":"8","author":"Zane","year":"2016","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.jaad.2023.12.048_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40257-016-0204-6","article-title":"Tolerability of crisaborole ointment for application on sensitive skin areas: a randomized, double-blind, vehicle-controlled study in healthy volunteers","volume":"17","author":"Zane","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.12.048_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/pde.12872","article-title":"Crisaborole topical ointment, 2% in patients 2 to 17 years of age with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure (MUSE) study","volume":"33","author":"Zane","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.12.048_bib23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5114\/ada.2019.91425","article-title":"Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials","volume":"36","author":"Ab\u0119d\u017a","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"issue":"4","key":"10.1016\/j.jaad.2023.12.048_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000506418","article-title":"Virtual clinical trials: perspectives in dermatology","volume":"236","author":"Ali","year":"2020","journal-title":"Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.12.048_bib25","doi-asserted-by":"crossref","DOI":"10.2196\/24766","article-title":"Remote rating of atopic dermatitis severity using photo-based assessments: proof-of-concept and reliability evaluation","volume":"5","author":"Ali","year":"2021","journal-title":"JMIR Form Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224000525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224000525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:00:37Z","timestamp":1717606837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224000525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0190962224000525"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.12.048","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of crisaborole ointment, 2%, in participants aged \u226545\u00a0years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.12.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}